Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

被引:47
作者
Blade, Joan [1 ]
Sonneveld, Pieter [2 ]
Miguel, Jesus E. San [3 ]
Sutherland, Heather J. [4 ]
Hajek, Roman [5 ,6 ]
Nagler, Arnon [7 ]
Spencer, Andrew [8 ]
Robak, Tadeusz [9 ]
Cibeira, M. Teresa [1 ]
Zhuang, Sen H.
Harousseau, Jean-Luc [10 ]
Orlowski, Robert Z. [11 ,12 ]
机构
[1] Univ Barcelona, Hosp Clin, Dept Hematol, IDIBAPS, E-08036 Barcelona, Spain
[2] Erasmus MC, Rotterdam, Netherlands
[3] Univ Hosp Salamanca, Ctr Canc Invest IBMCC CSIC USAL, Dept Hematol, Salamanca, Spain
[4] Leukemia Bone Marrow Transplant Program British C, Vancouver, BC, Canada
[5] Univ Hosp, Dept Internal Med & Hematooncol, Brno, Czech Republic
[6] Masaryk Univ, Fac Med, Brno, Czech Republic
[7] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[8] Monash Univ, Alfred Hosp, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic 3181, Australia
[9] Med Univ Lodz, Dept Hematol, Lodz, Poland
[10] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[12] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
Creatinine clearance; Paraprotein reduction; Thrombocytopenia;
D O I
10.3816/CLM.2008.n.051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib +/- pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and ! 60 mL/min, respectively).
引用
收藏
页码:352 / 355
页数:4
相关论文
共 14 条
[1]   How does proteinuria cause progressive renal damage? [J].
Abbate, Mauro ;
Zoja, Carla ;
Remuzzi, Giuseppe .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (11) :2974-2984
[2]   Renal failure in multiple myeloma -: Presenting features and predictors of outcome in 94 patients from a single institution [J].
Bladé, J ;
Fernández-Llama, P ;
Bosch, F ;
Montoliu, J ;
Lens, XM ;
Montoto, S ;
Cases, A ;
Darnell, A ;
Rozman, C ;
Montserrat, E .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (17) :1889-1893
[3]  
Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
[4]   Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [J].
Chanan-Khan, Asher A. ;
Kaufman, Jonathan L. ;
Mehta, Jayesh ;
Richardson, Paul G. ;
Miller, Kena C. ;
Lonial, Sagar ;
Munshi, Nikhil C. ;
Schlossman, Robert ;
Tariman, Joseph ;
Singhal, Seema .
BLOOD, 2007, 109 (06) :2604-2606
[5]   International uniform response criteria for multiple myeloma [J].
Durie, B. G. M. ;
Harousseau, J-L ;
Miguel, J. S. ;
Blade, J. ;
Barlogie, B. ;
Anderson, K. ;
Gertz, M. ;
Dimopoulos, M. ;
Westin, J. ;
Sonneveld, P. ;
Ludwig, H. ;
Gahrton, G. ;
Beksac, M. ;
Crowley, J. ;
Belch, A. ;
Boccadaro, M. ;
Turesson, I. ;
Joshua, D. ;
Vesole, D. ;
Kyle, R. ;
Alexanian, R. ;
Tricot, G. ;
Attal, M. ;
Merlini, G. ;
Powles, R. ;
Richardson, P. ;
Shimizu, K. ;
Tosi, P. ;
Morgan, G. ;
Rajkumar, S. V. .
LEUKEMIA, 2006, 20 (09) :1467-1473
[6]   Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function [J].
Jagannath, S ;
Barlogie, B ;
Berenson, JR ;
Singhal, S ;
Alexanian, R ;
Srkalovic, G ;
Orlowski, RZ ;
Richardson, PG ;
Anderson, J ;
Nix, D ;
Esseltine, DL ;
Anderson, KC .
CANCER, 2005, 103 (06) :1195-1200
[7]   Renal failure in multiple myeloma: reversibility and impact on the prognosis [J].
Knudsen, LM ;
Hjorth, M ;
Hippe, E .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2000, 65 (03) :175-181
[8]   Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma [J].
Ludwig, Heinz ;
Drach, Johannes ;
Graf, Helmut ;
Lang, Alois ;
Meran, Johannes Gobertus .
HAEMATOLOGICA, 2007, 92 (10) :1411-1414
[9]   Tubular NF-κB and AP-1 activation in human proteinuric renal disease [J].
Mezzano, SA ;
Barría, M ;
Droguett, MA ;
Burgos, ME ;
Ardiles, LG ;
Flores, C ;
Egido, J .
KIDNEY INTERNATIONAL, 2001, 60 (04) :1366-1377
[10]  
Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200/JCO.2006.10.5460